Diverging fates of cells of origin in acute and chronic leukaemia

The large difference in phenotypes among tumour populations may stem from the stochastic origin of tumours from distinct cells – tumour cells are assumed to retain the phenotypes of the cells from which they derive. Yet, functional studies addressing the cellular origin of leukaemia are lacking. Her...

Full description

Saved in:
Bibliographic Details
Published in:EMBO molecular medicine Vol. 4; no. 4; pp. 283 - 297
Main Authors: Kovacic, Boris, Hoelbl, Andrea, Litos, Gabriele, Alacakaptan, Memetcan, Schuster, Christian, Fischhuber, Katrin M., Kerenyi, Marc A., Stengl, Gabriele, Moriggl, Richard, Sexl, Veronika, Beug, Hartmut
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 01-04-2012
WILEY‐VCH Verlag
EMBO Press
WILEY-VCH Verlag
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The large difference in phenotypes among tumour populations may stem from the stochastic origin of tumours from distinct cells – tumour cells are assumed to retain the phenotypes of the cells from which they derive. Yet, functional studies addressing the cellular origin of leukaemia are lacking. Here we show that the cells of origin of both, BCR/ABL‐induced chronic myeloid (CML) and B‐cell acute lymphoid leukaemia (B‐ALL), resemble long‐term haematopoietic stem cells (LT‐HSCs). During disease‐maintenance, CML LT‐HSCs persist to function as cancer stem cells (CSCs) that maintain leukaemia and require signalling by the transcription factor STAT5. In contrast, B‐ALL LT‐HSCs differentiate into CSCs that correspond to pro‐B cells. This transition step requires a transient IL‐7 signal and is lost in IL‐7Rα‐deficient cells. Thus, in BCR/ABLp185 + B‐ALL and BCR/ABLp210 + CML, the final phenotype of the tumour as well as the abundance of CSCs is dictated by diverging differentiation fates of their common cells of origin.
Bibliography:Present address: German Cancer Research Centre (DKFZ), D-69120 Heidelberg, Germany
Present address: Department of Hematology/Oncology, Children's Hospital, Harvard Medical School, 1 Blackfan Circle, Karp Research Building 7th floor, Boston, MA 02115
ISSN:1757-4676
1757-4684
DOI:10.1002/emmm.201100208